ZFYVE27

Across TCGA pan-cancer cohorts, ZFYVE27 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZFYVE27 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZFYVE27 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZFYVE27 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where ZFYVE27 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.726	1.000	.007	13	view →
LUAD	OS	Median	II,III,IV	0.436	0.814	.013	7	view →
PDAC	OS	Median	II,III,IV	0.761	0.404	.005	4	view →
GBM	DFS	Tertile	All	0.833	0.618	.045	3	view →
HNSC	DFS	Tertile	III,IV	0.670	0.879	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZFYVE27–CCRCC (DFS)

Open the CCRCC breakdown →